Biogen Surges On A Setback For Eli Lilly’s Rival Alzheimer’s Treatment
Investor's Business DailyBiogen stock jumped Friday after the FDA delayed its approval decision on Eli Lilly’s rival Alzheimer’s treatment, donanemab.
The post Biogen Surges On A Setback For Eli Lilly's Rival Alzheimer's Treatment appeared first on Investor's Bu…